Introduction {#Sec1}
============

Chemotherapy in patients with biliary tract cancer is indicated in those with unresectable advanced cancer and patients with recurrence after resection. However, no standard chemotherapy for biliary tract cancer has yet been established, because few randomized controlled trials (RCTs) with large numbers of patients have been conducted to date. There are a number of studies regarding chemotherapy for biliary tract cancer, but many of these studies were prospective clinical trials with small numbers of patients, corresponding to phase II studies, or retrospective studies, so high-level evidence in this area is limited. According to the "Classification of Biliary Tract Carcinoma", bile duct cancer, gallbladder cancer, and ampullary cancer are classified as biliary tract cancer, and there are some clinical trials and articles in which treatment results that include those in intrahepatic bile duct cancer are also reported. If clinical trials are conducted for individual diseases separately, difficulties are encountered in view of efficiency and implementation, and so far, clinical trials of chemotherapy have been carried out only for biliary tract cancer in general. However, because treatment policy, sensitivity to chemotherapy, and prognosis differ widely from disease to disease, the treatment results of chemotherapy in biliary tract cancer should be evaluated on the basis of a full understanding of individual background factors.

In the present guidelines, chemotherapy for unresectable biliary tract cancer and postoperative adjuvant chemotherapy has been described based on results from clinical trials and retrospective studies performed up to now. In order that effective chemotherapy for biliary tract cancer may be developed, active implementation of clinical trials is recommended. Also, large multi-institutional RCTs (phase III) should be conducted to establish standard treatment as soon as possible.

The only procedure in biliary cancer that confers a cure is curative surgical resection, so a diagnosis of incurability should be made with caution. Lest the cancer be benign, surgical treatment should be administered as a rule only after pathological diagnosis (such as cytological and histological diagnoses) has been made. The chemotherapy described in the these Guidelines is concerned with adenocarcinoma, which has the highest frequency of occurrence, so pertinent literature should be referred to in selecting treatment methods for other specific pathological types of cancer. In these Guidelines, clinical questions (CQs) are posed, with responses in the form of recommendations (grades of the recommendations are defined in Table [1](#Tab1){ref-type="table"}[@CR1]). Also, levels of evidence are given (in parentheses) for findings in reference citations (see definitions of levels in Table [2](#Tab2){ref-type="table"}[@CR1]). Table 1Strength of recommendations^1^A, Strongly recommend performing the clinical actionB, Recommend performing the clinical actionC1, The clinical action may be considered although there is a lack of high-level scientific evidence for its use. May be usefulC2, Clinical action not definitively recommended because of insufficient scientific evidence. Evidence insufficient to support or deny usefulnessD, Recommend not performing the clinical actionTable 2Levels of evidence^1^Level ISystematic review/meta-analysisLevel IIOne or more randomized clinical trialsLevel IIINonrandomized controlled trialsLevel IVAnalytic epidemiology (cohort studies and case-control studies)Level VDescriptive study (case reports and case-series studies)Level VIOpinions of expert panels and individual experts not based on patient's data

CQ 1 Does chemotherapy have any benefits in patients with unresectable biliary tract cancer? {#Sec2}
============================================================================================

Chemotherapy is recommended in patients with good general physical condition (recommendation C1).

To assess the efficacy of chemotherapy in achieving prolonged survival in biliary tract cancer, verification is necessary by comparing it with supportive treatment alone. To date, only two small RCTs (level II) have been published.[@CR2],[@CR3]

An RCT on chemotherapy and supportive treatment was conducted in patients with unresectable pancreas cancer and biliary tract cancer.[@CR2] In this study, fluorouracil (5-FU) + leucovorin or 5-FU + leucovorin + etoposide were used for chemotherapy. For all the patients, significantly prolonged survival was observed in the group who received chemotherapy (median survival time \[MST\], 6.0 months) compared with the group who received supportive treatment alone (MST, 2.5 months). However, due to the small number of patients with biliary tract cancer (37 patients), no significant difference was established between the groups (chemotherapy group MST, 6.5 months; supportive treatment group, 2.5 months; *P* = 0.1). The rate of improvement in quality of life (QOL) was also examined in this trial, and a significant difference was found in the chemotherapy group compared with the supportive treatment group (*P* \< 0.01); an improvement of 36% was observed in the chemotherapy group (pancreas cancer, 38%; biliary tract cancer, 33%) and an improvement of 10% (pancreas cancer, 13%; biliary tract cancer, 5%) was shown in the supportive treatment group.

The other small RCT[@CR3] was conducted in Japan, comparing chemotherapy with 5-FU + doxorubicin + mitomycin C (FAM) and palliative treatment, such as bypass, in patients with unresectable pancreatic cancer, gallbladder cancer, and bile duct cancer. No significant improvement in prognosis was achieved in either group, but in the patients with gallbladder cancer, a good prognosis was achieved in the chemotherapy group (level II).

A retrospective analysis comparing chemotherapy and supportive treatment in patients with gallbladder cancer was carried out. No survival benefit owing to chemotherapy was observed in patients with a performance status of 2, while prolonged survival in the chemotherapy group was observed in patients with a performance status of 0 or 1[@CR4] (level IV).

Concerning the efficacy of chemotherapy for unresectable biliary tract cancer, no evidence based on an RCT with a large number of patients is available, but there are reports demonstrating the efficacy of chemotherapy in achieving improved QOL and prolonged survival. Thus, the strength of the recommendation for chemotherapy was determined as C1.[@CR2]--[@CR4]

The use of chemotherapy for biliary tract cancer should be limited to patients with unresectable, locally advanced disease and distant metastasis, or those with recurrence after resection. Chemotherapy is recommended in patients with a good general condition. However, in patients with general deterioration (performance status of 2 or 3) or those with insufficient biliary decompression, the benefit of chemotherapy is small, so care should be taken in considering its indications. In these patients, palliative treatment targeting the maintenance of QOL should be administered, including pain control and the placement of stents in the bile duct.

CQ 2 What is a recommended chemotherapy regimen? {#Sec3}
================================================

As chemotherapy for unresectable advanced biliary tract carcinoma, gemcitabine or tegafur/gimeracil/oteracil potassium is recommended (recommendation C1).

Table [3](#Tab3){ref-type="table"} shows the results of systemic chemotherapy with a single agent for biliary tract cancer. The single use of fluoropyrimidines such as 5-FU, or a combination of 5-FU with interferon, leucovorin, or hydroxyurea as biochemical modulators, was often used for advanced biliary tract cancer. A favorable response rate of more than 30% has been reported with the combined use of a single agent with these modulators, but no difference was observed in MST, which ranged from 7 to 12 months, in studies in patients undergoing chemotherapy for unresectable biliary tract cancer, compared with patients who received best supportive care (level III). In Japan, uracil-tegafur (UFT) is approved by the Ministry of Health, Labor, and Welfare for biliary tract cancer. However, regimens of UFT alone or UFT plus leucovorin were reported to have objective responses of 5% and 0%, respectively, and more than 60% patients were evaluated as having progressive disease in these regimen. Therefore, UFT should not be used alone for biliary tract cancer (level III). Table 3Systemic chemotherapy with single agents for biliary tract cancerAgent~n~Response rateMST (months)Study designEvidence levelAuthorYearReferenceFluorouracil5-FU180%--RCTLevel IITakada1994195-FU/LV/HU3030%8.0Cohort studyLevel IIIGebbia1996225-FU/α-IFN3234%12.0Cohort studyLevel IIIPatt1996235-FU/LV1833%7.0Cohort studyLevel IIIChen1998245-FU/LV2832%6.0Cohort studyLevel IIIChoi2000255-FU/FA307%14.8Cohort studyLevel IIIMalik200326UFT/LV130%6.5Cohort studyLevel IIIMani19995UFT/LV160%4.5Cohort studyLevel IIIChen20036Capecitabine2619%CC, 8.1; GB, 9.9Cohort studyLevel IIIPatt200427S-11921%8.3Cohort studyLevel IIIUeno200428UFT195%8.8Cohort studyLevel IIIIkeda20057S-1400%9.4Cohort studyLevel IIIFurusein press9TaxanesPaclitaxel150%--Cohort studyLevel IIIJones199629Docetaxel160%--Cohort studyLevel IIIPazdur199930Docetaxel2420%8.0Cohort studyLevel IIIPapakostas200131GemcitabineGemcitabine (800 mg/m^2^)3030%14.0Cohort studyLevel IIITsavaris200432Gemcitabine (1000 mg/m^2^)2536%7.0Cohort studyLevel IIIGallardo200133Gemcitabine (1000 mg/m^2^)2413%7.2Cohort studyLevel IIILin200334Gemcitabine (1000 mg/m^2^)4018%7.6Cohort studyLevel IIIOkusaka20068Gemcitabine (1200 mg/m^2^)196%6.5Cohort studyLevel IIIRaderer199935Gemcitabine (2200mg/m^2^)150%4.6Cohort studyLevel IIIEng200436Gemcitabine (2200 mg/m^2^)3222%11.5Cohort studyLevel IIIPenz200127OthersMitomycin C3010%4.5Cohort studyLevel IIITaal199338Cisplatin138%5.5Cohort studyLevel IIIOkada199439Irinotecan368%6.1Cohort studyLevel IIIAlberts200240Erlotinib428%7.5Cohort studyLevel IIIPhilip200614MST, median survival time; 5-FU, 5-fluorouracil; IFN, interferon; LV, levofolinic acid; FA, folinic acid; HU, hydroxyurea; CC, cholangiocarcinoma; GB gallbladder

Side memo {#Sec4}
=========

In Japan, none of the above modulators are approved by the Ministry of Health, Labour, and Welfare for use as chemotherapeutic drugs in biliary tract cancer.

Since 1999, clinical trials have been conducted with gemcitabine. Although methods of administration are different, relatively good results are reported (Table [3](#Tab3){ref-type="table"}). A clinical trial (phase II) was carried out with gemcitabine alone in Japan.[@CR8] A response rate of 17.5% (95% confidence intervals \[CI\], 7.3%--32.8%), and an MST of 7.6 months was achieved with the standard dosage, which was 1000 mg/m^2^ as a 30-min intravenous infusion weekly, given for 3 consecutive weeks, followed by a week of rest, the results being roughly similar to those of reports from abroad. Toxicity inducing myelosuppression, such as leucopenia, as well as nausea and anorexia, was mainly observed, but tolerance was good. Based on these results, gemcitabine was approved by the Ministry of Health, Labour, and Welfare, in June, 2006, for use in biliary tract cancer (level III).

A clinical trial of tegafur/gimeracil/oteracil potassium (S-1), which is an oral anticancer drug that consists of tegafur (FT) as a prodrug of 5-FU, 5-chloro-2, 4-dihydroxypyridine (CDHP), and potassium oxonate (Oxo), was conducted in Japan. S-1 was orally administered at a dose of 80 mg/m^2^ per day for 28 days, followed by 14 days of rest. In a late phase II trial, a favorable result was reported, with a success rate of 35% and MST of 9.4 months in 40 patients. Because of this result, insurance coverage for the use of this agent for biliary tract cancer was endorsed in August, 2007 (level III).

There are also some reports of the use of mitomycin C, cisplatin, taxanes, and irinotecan (CPT-11) (Table [3](#Tab3){ref-type="table"}), but no satisfactory result has been achieved (level III).

For biliary tract cancer, there is a limitation in treatment effects brought about by chemotherapy with the use of a single agent, so many modalities of combination chemotherapy have been carried out (Table [4](#Tab4){ref-type="table"}). Compared with single-agent chemotherapy, the response rate of combination chemotherapy is generally high and the survival period is also inclined to be long. Although a regimen of a combination of 5-FU, anthracycline, and platinum has often been employed, no standard regimen has been established. An attempt at a regimen focusing on the use of gemcitabine is currently being made and a favorable result has been achieved, with the response rate being 21%--48% and MST, 4.6--11.0 months in patients treated with gemcitabine + cisplatin[@CR10]--[@CR13] (level III). Currently, a large controlled trial comparing gemcitabine alone and gemcitabine + cisplatin (CDDP) is being conducted chiefly by an English group and it is drawing attention. Also, therapeutic drugs targeting molecular biological characteristics (molecular targeting therapy) are now under development. In view of a report suggesting the strong expression of epithelial growth factor receptor (EGFR) in biliary tract cancer, a phase II trial using erlotinib, which is an EGFRinhibiting drug, is being carried out.[@CR14]Table 4Combination chemotherapy for biliary tract cancerRegimen*n*Response rateMST (months)Study designEvidence levelAuthorYearReference5-FU-based5-FU/ADM/MMC (FAM)1429%8.5Cohort studyLevel IIIHarvey198441EPI/MTX/5-FU/LV170%9.0Cohort studyLevel IIIKajanti1994425-FU/LV/MMC2025%9.5Cohort studyLevel IIIRaderer199935MMC/5-FU/LV1926%6.0Cohort studyLevel IIIChen200143Platinum-basedEPI/CDDP/5-FU (ECF)2040%11.0Cohort studyLevel IIIEllis199544CDDP/EPI/5-FU (CEF)3719%5.9Cohort studyLevel IIIMorizane2003455-FU/CDDP2524%10.0Cohort studyLevel IIIDucreux1998465-FU/CDDP/LV2934%9.5Cohort studyLevel IIITaieb200247Capecitabine/CDDP4221%9.1Cohort studyLevel IIIKim TW200348CDDP/IFN/DXR/5-FU (PIAF)3821%14.0Cohort studyLevel IIIPatt200149EPI/CDDP/UFT/LV4023%7.9Cohort studyLevel IIIPark KH200550EPI/CDDP/capecitabine4340%8.0Cohort studyLevel IIIPark SH2006515-FU/LV/Carboplatin1421%5.0Cohort studyLevel IIISanz-Altamira1998525-FU/LV/Oxaliplatin (FOLFOX)1619%9.5Cohort studyLevel IIINehls200253Gemcitabine-basedGemcitabine/Docetaxel439%11.0Cohort studyLevel IIIKuhn200254Gemcitabine/5-FU2733%5.3Cohort studyLevel IIIKnox200455Gemcitabine/5-FU/LV4212%4.7Cohort studyLevel IIIHsu200456Gemcitabine/5-FU/LV4212%9.7Cohort studyLevel IIIAlberts200557Gemcitabine/CDDP3038%4.6Cohort studyLevel IIIDoval200410Gemcitabine/CDDP4028%8.4Cohort studyLevel IIIThongprasert200511Gemcitabine/CDDP2935%11.0Cohort studyLevel IIIKim ST200612Gemcitabine/CDDP2733%10.0Cohort studyLevel IIIPark BK200613Gemcitabine/oxaliplatin3333%15.4Cohort studyLevel IIIAndre200458Gemcitabine/capecitabine4531%14.0Cohort studyLevel IIIKnox200516Gemcitabine/capecitabine4532%14.0Cohort studyLevel IIICho200559MST, median survival time; MTX, methotrexate; MMC, Mitomycin C; 5-FU, 5-fluorouracil; LV, leucovorin; IFN, interferon

In biliary tract cancer, treatment results differ widely depending upon the site of the cancer. In clinical trials, patients' backgrounds, particularly the proportions of those with gallbladder cancer, bile duct cancer, and ampullary cancer, have a big impact on treatment results, such as the survival period.[@CR7],[@CR15],[@CR16] In a phase II study of gemcitabine + capecitabine, the MST in patients with gallbladder cancer was 6.6 months and the MST in patients with bile duct cancer was 19 months; thus, this difference in MST was assumed to be due to a biological difference.[@CR16] In overseas clinical trials of chemotherapy for biliary tract cancer, intrahepatic cholangiocarcinoma is often included. In Japan, however, intrahepatic cholangiocarcinoma was often excluded from clinical trials of biliary tract cancer, because this entity is classified as primary liver cancer in the "General rules for the clinical and pathological study of primary liver cancer,[@CR17]" published by the Liver Cancer Study Group of Japan[@CR18] and the "TNM classification of malignant tumours," published by the International Union Against Cancer. Also, some clinical trials include ampullary cancer and some do not. Ideally, clinical trials of chemotherapy for biliary tract cancer and the assessment of treatment results should be carried out independently according to the individual diseases, but due to the small numbers of patients with the individual diseases, making an analysis of diseases independently is difficult. Therefore, RCTs with large numbers of patients and adequate stratification of all patients concerned should be conducted to evaluate the results of chemotherapy.

The number of RCTs that have been conducted concerning chemotherapy for bile duct cancer is not so large. Outlined in Table [5](#Tab5){ref-type="table"} are RCTs retrieved from a literature search. In Japan, comparisons were made by Takada et al.[@CR3],[@CR19] between FAM and 5-FU alone and between FAM and palliative treatment, such as bypass operation. No significant difference in survival was confirmed in these RCTs, and a standard chemotherapy has not been established yet (level II). Table 5Randomized clinical trials for unresectable biliary tract cancer*n*Response rateMST (months) GB/BD*P* valueStudy designEvidence levelAuthor (year)Reference1) Oral 5-FU3010%4.9/6.1NSRCTLevel IIFalkson (1984)602) Oral 5-FU + Stz267.7%3.3/2.83) Oral 5-FU + MeCCNU319.7%2.3/1.91) Modified FAM35 (18)^a^4%6.2^b^NSRCTLevel IITakada (1994)192) 5-FU36 (18)^a^0%6.0^b^1) 5-FU + LV or FELV47 (18)^a^11%6.5 (6.5)^b^0.1RCTLevel IIGlimelius (1996)22) BSC43 (19)^a^--2.5 (2.5)^b^1) Modified FAM14--5.2/4.1NSRCTLevel IITakada (1998)32) Palliative surgery17--2.4/7.71) MMC + gemcitabine2520%6.7--RCTLevel IIKornek (2004)612) MMC + capecitabine2631%9.31) 5-FU29--5.0--RCTLevel IIDucreux (2005)622) 5-FU + FA + cisplatin29--8.01) ECF27--9.00.72RCTLevel IIRao (2005)632) FELV27--12.0MST, median survival time; GB, gallbladder; BD, bile duct; Stz, streptozotocin; MeCCNU, methyl-CCNU; LV, levofolinic acid (lecovorin); BSC, best supportive care; MMC, mitomycin C; FA, folinic acid; FAM, 5-FU + adriamycin + MMC; FELV, 5-FU + etoposide + leucovorin; ECF, epirubicin + cisplatin + 5-FU^a^ The total number of patients in the study, including those with pancreatic cancer; numbers in parentheses, numbers of patients with biliary tract cancer^b^ The median overall survival time in all patients in the study, including those with pancreatic cancer; numbers in parentheses, median overall survival times in patients with biliary tract cancer

As chemotherapy for biliary tract cancer at the present time, gemcitabine or S-1, which is covered by insurance in Japan, is recommended on the basis of the results of many phase II trials, including those performed in Japan (level III). Evidence-based standard treatment should be established in the future by conducting controlled trials with the use of these agents.

CQ 3 Does adjuvant chemotherapy after surgery have a survival benefit? {#Sec5}
======================================================================

No recommendable regimen is available now, but it is hoped that adjuvant chemotherapy can be carried out as a clinical trial. (recommendation C1).

In gallbladder and bile duct cancers, early recurrence often occurs even if these patients have received curative resection; the prognosis in patients with recurrence is extremely poor. Therefore, further development of effective measures for preventing recurrence through postoperative adjuvant therapy is eagerly anticipated. In view of the low incidence of biliary tract cancer in Western countries, where a large number of clinical studies of postoperative adjuvant therapy have been conducted in other types of cancer, few RCTs of postoperative adjuvant therapy for biliary tract cancer have been carried out. On the other hand, in the East Asian region (including Japan), the incidence of biliary tract cancer is high so RCTs of postoperative adjuvant therapy have been carried out in Japan.

From 1986 to 1992, Takada et al. performed an RCT in which 508 patients with pancreas cancer and biliary tract cancer were assigned to a group in which combination chemotherapy using 5-FU and mitomycin C (MMC) was administered (MF group) and a group for whom surgery alone was conducted (control group); the results were reported with a postoperative follow-up period of 5 years.[@CR20] As eligible patients, 158 patients with pancreatic cancer, 118 patients with bile duct cancer, 112 patients with gallbladder cancer, and 48 patients with ampullary cancer were chosen. Analysis was done independently in the individual diseases, and the 5-year survival rate was found to be significantly better in the MF group for gallbladder cancer (Table [6](#Tab6){ref-type="table"}) (level II). However, according to a review of the degree of cure due to resection, a significant difference in survival rate was found only in patients with noncurative resection. On the basis of an intent-to-treat analysis, no significant difference between the MF and the control group was observed in patients with gallbladder cancer. MF therapy has not yet been established as standard postoperative adjuvant therapy in biliary tract cancer, but the efficacy of postoperative adjuvant therapy is suggested by such trials. Table 6Randomized clinical trial of adjuvant chemotherapy for pancreas and biliary tract cancer^20^*n*5-Year survival rate*P* valuePancreasMitomycin C/5-FU8111.5%NSSurgery alone7718.0%GallbladderMitomycin C/5-FU6926.0%0.037Surgery alone4314.4%Biliary tractMitomycin C/5-FU5826.7%NSSurgery alone6024.1%Ampulla of VaterMitomycin C/5-FU2428.1%NSSurgery alone2434.3%

Todoroki summarized the results of clinical trials of chemotherapy for gallbladder cancer and verified that postoperative chemotherapy was efficacious. Most of these clinical trials were conducted using a single arm, so no regimen could be selected as a possible candidate for postoperative adjuvant therapy.[@CR21] Recently, chemotherapy focusing on gemcitabine for unresectable biliary tract cancer has been conducted, and regimens with good anticancer effects have sometimes been observed. However, no large RCTs of postoperative adjuvant therapy have been carried out with the use of such regimens. RCTs of postoperative adjuvant therapy, using new agents including gemcitabine and S-1, should be conducted vigorously. At the present time, no recommendable postoperative adjuvant therapy has been discovered, so clinical trials of various forms of chemotherapy are anticipated in the future.
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